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Introduction
As a result of the progressive decline in functional
insulin-producing beta cells, the majority of patients
with type 2 diabetes eventually require combination
drug therapy to achieve and maintain glycaemic tar-
gets (1–3). The availability of newer agents may
allow for different therapeutic combinations to
improve glycaemic control without increasing the
risk of adverse effects (4,5).
Saxagliptin is a potent, selective dipeptidyl pepti-
dase-4 (DPP-4) inhibitor, specifically designed for
extended inhibition of the DPP-4 enzyme (6,7).
DPP-4 inhibitors enhance the levels of the glucoregu-
latory hormones glucagon-like peptide-1 (GLP-1)
and glucose-dependent insulinotropic peptide (GIP),
thereby acting to promote insulin synthesis and
release, and suppress glucagon secretion, among
other important glucoregulatory effects (8). DPP-4
inhibitors are associated with a favourable safety pro-
file, including a low risk of hypoglycaemia because of
the glucose-dependent nature of incretin hormone
activity, a neutral effect on body weight and the
potential for improved beta-cell function (8,9). Proof
of concept for saxagliptin was previously established
in a 12-week dose-ranging trial (dose range: 2.5–
40 mg) (6,7). In a phase 3 clinical trial, saxagliptin
administered as initial therapy with metformin
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What’s known
• Initial antihyperglycaemic monotherapy is
frequently insufficient to enable patients with
type 2 diabetes to achieve or sustain glycaemic
targets.
• Sulphonylurea therapy has demonstrated efficacy
in improving glycaemic control; however, it is
also associated with limitations, including the
potential for weight gain and an increased risk of
hypoglycaemia with sulphonylurea-induced
hyperinsulinaemia.
What’s new
• The availability of newer agents such as
dipeptidyl peptidase-4 inhibitors may allow for
additional therapeutic combinations to improve
glycaemic control without significantly increasing
the risk of adverse effects.
• This study evaluated the safety and efficacy of
saxagliptin added to submaximal-dose
sulphonylurea (glyburide) therapy, compared with
uptitration of sulphonylurea (glyburide)
monotherapy for 24 weeks in patients with
inadequate glycaemic control with submaximal-
dose sulphonylurea therapy alone.
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improved glycaemic control and was well tolerated
in patients with type 2 diabetes (10).
Sulphonylureas are among the most frequently
prescribed and least costly oral antidiabetic drugs
(OADs); their mechanism of action involves binding
to the beta-cell sulphonylurea receptor 1, which ulti-
mately stimulates insulin release (11,12). While spe-
cific guidelines vary, sulphonylureas are most often
recommended as second-line therapy (after metfor-
min) (13) and in some cases, as first-line OAD
therapy in patients who are not overweight (12).
Studies have demonstrated clinically significant
improvements in glycaemic control with sulphonyl-
urea therapy. However, as monotherapy, 5-year fail-
ure rates based on a fasting plasma glucose (FPG)
> 10.0 mmol ⁄ l after at least 6 weeks of treatment at
the maximum dose are approximately 34% (3,11).
Sulphonylurea therapy is associated with limitations,
including the potential for beta-cell toxicity, weight
gain and an increased risk of hypoglycaemia with
sulphonylurea-induced hyperinsulinaemia (5,11,14–
16). Combination therapy of a DPP-4 inhibitor with
a submaximal dose of a sulphonylurea represents an
alternative treatment approach that may provide
improved glycaemic control earlier in the disease
course and allow the use of lower doses of sulpho-
nylurea to reduce the risk for dose-related adverse
events (AEs) (17,18).
The current trial evaluated the safety and efficacy
of saxagliptin added to submaximal-dose sulphonyl-
urea (glyburide) therapy, compared with uptitration
of sulphonylurea (glyburide) monotherapy, in
patients with type 2 diabetes and inadequate glycae-
mic control with submaximal-dose sulphonylurea
therapy alone.
Patients and methods
Patients
Patients aged 18)77 years (inclusive) with type 2
diabetes and inadequate glycaemic control (HbA1c
screening value ‡ 7.5 to £ 10.0%) on a submaximal
sulphonylurea dose [defined as less than the maxi-
mum approved dose for each sulphonylurea (see
Table S1 for list of sulphonylureas and doses)] for
‡ 2 months before screening and with fasting C-pep-
tide ‡ 1.0 ng ⁄ml (0.3 nmol ⁄ l) and body mass index
(BMI) £ 40 kg ⁄m2 were eligible. Exclusion criteria
included symptoms of poorly controlled diabetes;
history of diabetic ketoacidosis or hyperosmolar
non-ketotic coma; insulin therapy within 1 year of
screening; cardiovascular event within 6 months of
study entry or New York Heart Association
stage III ⁄ IV congestive heart failure and ⁄or known
left ventricular ejection fraction £ 40%; significant
history of renal or liver disease; psychiatric disorder;
history of alcohol or drug abuse within the previous
year; treatment with potent CYP 3A4 inhibitors or
inducers; immunocompromised individuals; active
liver disease or clinically significant abnormal hepa-
tic, renal, endocrine, metabolic or haematological
screening tests.
This study was conducted in accordance with
Good Clinical Practice, as defined by the Interna-
tional Conference on Harmonisation, and in
accordance with the ethical principles underlying
the European Union Directive 2001 ⁄ 20 ⁄ EC, the
United States Code of Federal Regulations, Title
21, Part 50 (21CFR50), and the Declaration of
Helsinki. Study protocol, amendments and patient
informed consent were approved by the Institu-
tional Review Board ⁄ Independent Ethics Commit-
tee at each site. All patients provided written,
informed consent.
Study design
This study (CV181-040) was a 24-week, phase 3,
randomised, multicentre, 3-arm, double-blind, inter-
national trial. Patients were recruited from outpatient
settings, advertisements, postings and referrals.
Eligible patients entered a 4-week, single-blind, die-
tary and exercise placebo lead-in period during
which they discontinued their current sulphonylurea
therapy and received open-label glyburide
7.5 mg ⁄day. Patients were instructed by a registered
dietitian, registered nurse, physician, certified
diabetes educator or nutritionist on diet and exercise
in accordance with the American Diabetes Associa-
tion (ADA) or similar local guidelines to be followed
for the study duration. Good compliance (‡ 80 to
£ 120%) with placebo was required to be eligible for
randomisation before the short-term treatment
period. Patients with an HbA1c level ‡ 7.0% and
mean FPG (MFPG) or FPG ‡ 140 mg ⁄dl
(7.8 mmol ⁄ l) or mean fasting whole blood glucose
(MFWBG) ‡ 131 mg ⁄dl (7.3 mmol ⁄ l) continued
treatment with open-label glyburide 7.5 mg ⁄day and
were randomised (1 : 1 : 1) via Interactive Voice
Response System to one of three treatment groups
(block size 3) utilising a double-dummy design: saxa-
gliptin 2.5 mg ⁄ day (saxagliptin 2.5 mg + glyburide),
saxagliptin 5 mg ⁄day (saxagliptin 5 mg + glyburide)
or placebo + blinded glyburide 2.5 mg ⁄day [uptitrat-
ed glyburide; initial total daily dose (TDD) of glybu-
ride 10 mg]. A one-time decrease in open-label
glyburide to 5 mg ⁄day was permitted at the investi-
gator’s discretion for patients who developed
hypoglycaemia. Uptitration of blinded glyburide
was permitted at weeks 2 and 4 in the uptitrated
glyburide treatment group for patients satisfying
1396 Saxagliptin added to submaximal-dose sulphonylurea
ª 2009 Bristol-Myers Squibb
Journal compilation ª 2009 Blackwell Publishing Ltd Int J Clin Pract, September 2009, 63, 9, 1395–1406
prespecified glycaemic criteria [MFPG ‡ 100 mg ⁄dl
(5.5 mmol ⁄ l) or MFWBG ‡ 95 mg ⁄ dl (5.3 mmol ⁄ l)]
to a maximum TDD of 15 mg (7.5 mg open-label +
7.5 mg blinded glyburide), provided the open-label
glyburide dose had not been previously decreased
because of hypoglycaemia. Throughout the study,
double-blind study medication was to be taken twice
daily, before the morning and evening meals to
allow the glyburide dose to be split between morning
and evening. Saxagliptin was to be taken in the
morning. Patients were eligible for rescue therapy
based on progressively strict glycaemic control
criteria over 24 weeks if MFPG levels were: > 240
mg ⁄dl (13.3 mmol ⁄ l) (weeks 4 and 6); > 220 mg ⁄dl
(12.2 mmol ⁄ l) (week 8); and > 200 mg ⁄ dl (11.1
mmol ⁄ l) (weeks 12, 16, 20 and 24), or if
MFWBG > 221 mg ⁄dl (12.3 mmol ⁄ l) (weeks 4 and
6); > 203 mg ⁄dl (11.3 mmol ⁄ l) (week 8); or
> 185 mg ⁄dl (10.3 mmol ⁄ l) (weeks 12, 16, 20 and
24). Patients meeting rescue criteria entered into the
long-term extension period, during which they were
administered open-label metformin and glyburide in
addition to blinded study medication. Patients com-
pleting 24 weeks of treatment without rescue also
entered the long-term extension period. Long-term
extension results will be reported in a future com-
munication.
Study end-points
Efficacy assessments
The primary efficacy end-point was HbA1c change
from baseline to week 24. Secondary efficacy end-
points assessed at week 24 and listed in the order
tested were change from baseline in FPG, propor-
tion of patients achieving HbA1c < 7.0%, and
change from baseline in postprandial glucose
(PPG) area under the curve (AUC) from 0 to
180 min in response to a 75-g oral glucose toler-
ance test (OGTT) with samples drawn at time
)30 min, immediately prior to time 0 min, and at
+30, +60, +120 and +180 min after oral glucose
ingestion. Other efficacy end-points included the
proportion of patients achieving HbA1c £ 6.5%;
change from baseline to week 24 in fasting insulin,
C-peptide and glucagon; postprandial insulin, C-
peptide and glucagon AUC; beta-cell function
[measured by homeostatic model assessment
(HOMA)-2b]; insulin resistance (measured using
HOMA-2IR); the proportion of patients requiring
rescue for failing to achieve prespecified glycae-
mic targets or discontinuing for lack of efficacy;
the proportion of patients achieving a glycaemic
response at week 24 based on prespecified criteria;
and PPG-AUC at the 120-min time point. Changes
from baseline to week 24 in body weight, lipid
parameters, insulinogenic index, Matsuda index
(19) and oral glucose insulin sensitivity (OGIS)
(20) were also examined. Subgroup analyses for
baseline HbA1c were prespecified.
Safety assessments
Safety and tolerability assessments included incidence
of AEs, serious AEs (SAEs), AE-related discontinua-
tions as well as results for electrocardiograms, vital
signs and clinical laboratory tests. AEs of hypogly-
caemia and confirmed hypoglycaemia, defined as
symptoms of hypoglycaemia with a fingerstick glu-
cose £ 2.8 mmol ⁄ l, were also recorded.
Statistical analyses
Efficacy analyses were conducted utilising data col-
lected at baseline and postbaseline in the Rando-
mised Patients data set, which consisted of all
randomised patients who took at least one dose of
double-blind study medication. An ANCOVA was
performed on continuous efficacy end-points using
last-observation-carried-forward (LOCF) methodol-
ogy with treatment group as an effect and baseline
value as the covariate. Within the framework of the
ANCOVA model, point estimates and 95% confi-
dence intervals were calculated for mean changes
between each of the saxagliptin treatment groups and
the uptitrated glyburide group. For the primary end-
point, each comparison between a saxagliptin treat-
ment group and the uptitrated glyburide group was
performed at the 0.027 alpha level from Dunnett’s
adjustment so that the overall (family-wise) type I
error rate was controlled at the 0.05 significance
level. Sequential testing methodology was used for
secondary efficacy end-points. At each step in the
testing sequence, only the saxagliptin treatment
groups that were significantly superior to uptitrated
glyburide were tested at the subsequent step. Sum-
maries of categorical end-points such as the percent-
age of patients achieving a therapeutic glycaemic
response at week 24, the proportion of patients
requiring rescue ⁄discontinuation because of lack of
glycaemic control and the proportion of patients
with reported and confirmed hypoglycaemia included
frequencies and percentages for each treatment
group; treatment groups were compared using the
two-sided Fisher exact test. Demographic and other
baseline characteristics were summarised using
descriptive statistics by treatment group. LOCF
methodology was used to handle missing data. The
adjusted mean changes from baseline within each
treatment group as well as the difference in mean
change from baseline between each treatment group
and the placebo or active comparator treatment
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group for each subgroup were calculated, as well as
the corresponding subgroup by treatment interaction
p-value. Systeme International (SI) conversion from
mg ⁄dl to mmol ⁄ l of glucose was calculated with the
equation: mg ⁄dl · 0.0555. All other SI conversions
pertaining to data presented for this study are noted
in Table S2. Estimated average glucose (eAG) values
were calculated post hoc based on HbA1c values using
the linear regression: eAGmg ⁄ dl = 28.7 · HbA1c )
46.7 (21).
Safety analyses were performed in the treated
patient population, consisting of patients who received
at least one dose of study medication. Events of
hypoglycaemia and confirmed hypoglycaemia were
recorded and analysed separately from other AEs.
Hypoglycaemic event intensity was graded according
to the investigator’s discretion, as were all other AEs.
Efficacy and safety measurements obtained after rescue
were not included in analyses.
Based on the primary end-point, the sample size
afforded at least 90% power to detect a difference in
HbA1c means of 0.4% between each saxagliptin treat-
ment group and the uptitrated glyburide treatment
group, assuming a standard deviation (SD) of 1.2%.
Results
Disposition, baseline demographics and
disease characteristics
A total of 768 patients were randomised and treated
with double-blind therapy; 563 patients completed
the 24-week treatment period (Figure 1). Demo-
graphic and baseline clinical characteristics were gen-
erally well balanced across all treatment groups
(Table 1). The mean (SD) duration of the previous
sulphonylurea treatment was 2.5 (3.54), 2.3 (2.96)
and 2.4 (3.60) years in the saxagliptin 2.5- and 5-mg,
and uptitrated glyburide groups, respectively. All
patients had been previously treated with a sulpho-
nylurea before study entry; 64% of patients received
prior glyburide treatment.
Saxagliptin-treated patients received a lower final
mean TDD (open-label and blinded) of glyburide vs.
the uptitrated glyburide group. Approximately, 92%
Figure 1 Flow of patients through the study. Recruitment period ran from 17 April 2006 through 2 February 2007, with
follow up ending on 14 September 2007. SAXA 2.5 mg + GLY = saxagliptin 2.5 mg ⁄ day plus open-label glyburide
7.5 mg ⁄ day. SAXA 5 mg + GLY = saxagliptin 5 mg ⁄ day plus open-label glyburide 7.5 mg ⁄ day. PBO + uptitrated
GLY = placebo plus double-blind glyburide 2.5 mg ⁄ day and open-label glyburide 7.5 mg ⁄ day
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of patients in the uptitrated glyburide group were
titrated to the maximum daily glyburide dose
(15 mg). The final mean (SD) glyburide TDD was
7.4 (0.5) mg (saxagliptin 2.5 mg), 7.4 (0.6) mg (saxa-
gliptin 5 mg) vs. 14.6 (1.3) mg (uptitrated glyburide
group). Open-label glyburide was downtitrated to
5 mg ⁄day in 4.0%, 5.1% and 2.2% of patients in the
saxagliptin 2.5- and 5-mg and uptitrated glyburide
groups, respectively, primarily in response to hypo-
glycaemia-related AEs.
Efficacy
At 24 weeks, patients randomised to saxagliptin 2.5
or 5 mg demonstrated statistically significant reduc-
tions in HbA1c, FPG and PPG-AUC from baseline,
compared with patients in the uptitrated glyburide
group. Baseline vs. week 24 HbA1c mean values were
8.4% vs. 7.8%; 8.5% vs. 7.8% and 8.4% vs. 8.5%
for saxagliptin 2.5 and 5 mg and uptitrated glybu-
ride respectively. Corresponding eAG values were
194 vs. 177 mg ⁄dl (10.8 vs. 9.8 mmol ⁄ l) for saxa-
gliptin 2.5 mg; 197 vs. 177 mg ⁄dl (10.9 vs.
9.8 mmol ⁄ l) for saxagliptin 5 mg; and 194 vs.
197 mg ⁄dl (10.8 vs. 10.9 mmol ⁄ l) for uptitrated
glyburide. Adjusted mean change in HbA1c from
baseline was )0.54% and )0.64% for saxagliptin 2.5
and 5 mg vs. +0.08% for uptitrated glyburide (both
p < 0.0001) (Figure 2A). Greater HbA1c mean
reductions were observed with saxagliptin therapy
vs. uptitrated glyburide at week 4, the earliest time
point assessed for HbA1c, and persisted at all subse-
quent time points (Figure 2B). The greatest HbA1c
reductions were demonstrated in the saxagliptin
5-mg treatment group.
Statistically significantly greater mean reductions
in FPG at week 24 were observed for saxagliptin 2.5
(p = 0.0218) and 5 mg (p = 0.002) vs. uptitrated
glyburide. Adjusted mean change from baseline was
)7 mg ⁄dl ()0.40 mmol ⁄ l) (saxagliptin 2.5 mg) and
)10 mg ⁄dl ()0.50 mmol ⁄ l) (saxagliptin 5 mg) vs.
+1 mg ⁄dl (+0.04 mmol ⁄ l) for uptitrated glyburide
(Figure 2C). Reductions in MFPG values were appar-
ent by week 2, the earliest time point for FPG assess-
ment (Figure 2D).
The proportion of patients achieving an HbA1c
< 7.0% at week 24 was statistically significantly
greater for saxagliptin 2.5 mg (22.4%) and saxaglip-
tin 5 mg (22.8%) vs. uptitrated glyburide (9.1%;
both p < 0.0001). The proportion of patients achiev-
ing an HbA1c £ 6.5% at week 24 was statistically sig-
nificantly greater for saxagliptin 5 mg (10.4%) vs.
uptitrated glyburide (4.5%; p = 0.0117).
Table 1 Baseline demographic and clinical characteristics by randomised group
Characteristic
SAXA 2.5 mg + GLY SAXA 5 mg + GLY PBO + UPGLY
(n = 248) (n = 253) (n = 267)
Age (years)* 55.4 (9.6) 54.9 (10.0) 55.1 (10.7)
Age ‡ 65 (years) 43 (17.3) 42 (16.6) 52 (19.5)
Gender
Men 113 (45.6) 110 (43.5) 123 (46.1)
Women 135 (54.4) 143 (56.5) 144 (53.9)
Race,
White 148 (59.7) 151 (59.7) 152 (56.9)
Black ⁄ African American 5 (2.0) 7 (2.8) 7 (2.6)
Asian 42 (16.9) 46 (18.2) 51 (19.1)
Other 53 (21.4) 49 (19.4) 57 (21.3)
Weight (kg)* 75.2 (14.4) 76.2 (17.6) 75.6 (17.4)
BMI (kg ⁄m2)* 29.1 (4.5) 29.2 (4.6) 28.8 (4.7)
Duration of diabetes (years)* 7.1 (5.9) 6.8 (5.8) 6.8 (5.7)
HbA1c (%)* 8.4 (0.9) 8.5 (0.9) 8.4 (0.9)
< 8% 88 (35.5) 74 (29.2) 93 (34.8)
‡ 8 to < 9% 101 (40.7) 102 (40.3) 99 (37.1)
‡ 9% 59 (23.8) 76 (30.0) 75 (28.1)
Not reported 0 (0) 1 (0.4) 0 (0)
FPG (mg ⁄ dl)* 170 (41.9) 175 (44.3) 175 (42.8)
BMI, body mass index; FPG, fasting plasma glucose. *Values are expressed as mean (SD). Values are expressed as n (%).
Race ⁄ ethnicity was self-reported. SAXA 2.5 mg + GLY = saxagliptin 2.5 mg ⁄ day plus open-label glyburide 7.5 mg ⁄ day. SAXA
5 mg + GLY = saxagliptin 5 mg ⁄ day plus open-label glyburide 7.5 mg ⁄ day. PBO + UPGLY = placebo plus double-blind glyburide
2.5 mg ⁄ day and open-label glyburide 7.5 mg ⁄ day.
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A statistically significant reduction in glucose
exposure from baseline to week 24 was seen in PPG-
AUC during the OGTT for the saxagliptin treatment
groups vs. uptitrated glyburide [)4296 mgÆmin ⁄dl
()238 mmolÆmin ⁄ l) and )5000 mgÆmin ⁄dl ()278
mmolÆmin ⁄ l) vs. +1196 mgÆmin ⁄dl (+66 mmolÆmin ⁄ l)
respectively, both p < 0.0001 vs. uptitrated glybu-
ride]. An overall decrease from baseline in mean glu-
cose concentration at all time points of the OGTT
occurred in both saxagliptin treatment groups com-
pared with increases in the uptitrated glyburide
group at week 24 (Figure 3). At the 120-min time
point of the OGTT, PPG adjusted mean changes
from baseline were )31 mg ⁄dl ()2 mmol ⁄ l) for saxa-
gliptin 2.5 mg and )34 mg ⁄dl ()2 mmol ⁄ l) for saxa-
gliptin 5 mg relative to +8 mg ⁄dl (+0.4 mmol ⁄ l) for
uptitrated glyburide, both p < 0.0001.
Changes in other efficacy assessments are listed in
Table 2. At week 24, saxagliptin treatment increased
postprandial insulin and C-peptide AUC to a greater
degree than did uptitrated glyburide. Saxagliptin
treatment did not have an effect on fasting insulin or
C-peptide. Postprandial glucagon AUC was decreased
to a greater degree with saxagliptin treatment vs.
uptitrated glyburide; decreases in fasting glucagon
were only noted in the saxagliptin 5-mg group
[)0.8 pg ⁄ml ()0.8 ng ⁄ l)] vs. uptitrated glyburide
[+4.5 pg ⁄ml (+4.5 ng ⁄ l)]. There was no change in
beta-cell function (HOMA-2b assessment) at week
24 in the saxagliptin treatment groups vs. uptitrated
glyburide. Similarly, saxagliptin treatment was not
associated with changes in early insulin response (as
measured using the 30-min insulinogenic index),
insulin sensitivity (based on OGIS and Matsuda indi-
ces) or insulin resistance (HOMA-2IR assessment)
vs. uptitrated glyburide. Mean body weight increased
in all treatment groups; adjusted mean increases were
statistically significantly greater in each saxagliptin
A
C D
B
Figure 2 Changes in glycaemic variables during 24-week treatment period: saxagliptin + MET vs. monotherapy. (A) HbA1c
adjusted mean change from baseline to week 24. (B) HbA1c mean change from baseline during 24-week treatment period.
(C) Fasting plasma glucose (FPG) adjusted mean change from baseline to week 24. (D) FPG mean change from baseline
during 24-week treatment period. Open bars (A and C) and open squares (B and D), saxagliptin 2.5 mg + GLY; grey bars
(A and C), and open circles (B and D), saxagliptin 5 mg + GLY; dark grey bars (A and C) and shaded circles (B and D),
placebo + UPGLY. ap < 0.0001; bp = 0.0218; cp = 0.0020
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treatment group vs. uptitrated glyburide [+0.7 kg
(p = 0.0381) and +0.8 kg (p = 0.0120) for saxaglip-
tin 2.5 and 5 mg respectively, vs. +0.3 kg for upti-
trated glyburide]. Saxagliptin had no clear effect on
mean fasting total cholesterol levels. All three treat-
ment groups experienced small numerical increases
in triglycerides and low-density lipoprotein-choles-
terol and numerical decreases in high-density lipo-
protein-cholesterol. HbA1c reductions were similar,
regardless of duration of diabetes, geographic region,
race, gender, age, ethnicity or BMI. No interaction of
treatment with baseline HbA1c was observed
(p = 0.5907).
The proportion of patients (n ⁄N) discontinuing
for lack of glycaemic control or rescued for meeting
prespecified glycaemic criteria was lower for saxaglip-
tin 2.5 mg [18.1% (45 ⁄ 248)] and 5 mg [16.6%
(42 ⁄ 253)] vs. uptitrated glyburide [29.6% (79 ⁄ 267)].
Safety and tolerability
Overall, saxagliptin added to submaximal glyburide
therapy was generally well tolerated. The proportion
of patients reporting any AE was similar across all
treatment groups, with no evidence of a dose–
response relationship (Table 3). One death (sudden
cardiac death) occurred in the uptitrated glyburide
group. The majority of AEs were mild or moderate
in intensity.
The proportion of patients with skin-related AEs
was: 8.9% [22 ⁄ 248 (saxagliptin 2.5 mg)], 4.7%
[12 ⁄ 253 (saxagliptin 5 mg)] and 4.9% [13 ⁄ 267 (upti-
trated glyburide)], with no evidence of a dose-related
effect. AEs related to localised oedema were reported
in two saxagliptin-treated patients: one in the saxa-
gliptin 2.5-mg group and one in the saxagliptin 5-
mg group; none were reported in the uptitrated
glyburide treatment group. Both events were
reported to be of mild intensity and not related to
study drug, and neither led to discontinuation. No
events of Stevens-Johnson syndrome or angio-
oedema were reported. Cardiac disorder events were:
2.0% (5 ⁄ 248) for saxagliptin 2.5 mg, 4.0% (10 ⁄ 253)
for saxagliptin 5 mg and 3.7% (10 ⁄ 267) for uptitrat-
ed glyburide. AEs of hypertension were reported for
9 ⁄ 248 (3.6%, saxagliptin 2.5 mg), 16 ⁄ 253 (6.3%,
saxagliptin 5 mg) and 6 ⁄ 267 (2.2%, uptitrated glybu-
ride) patients; however, mean systolic (SBP) and dia-
stolic blood pressure (DBP) decreased in all
treatment groups. The mean change from baseline at
week 24 for saxagliptin 2.5 and 5 mg, and uptitrated
–31b –34b
Figure 3 Postprandial glucose response to 3-h OGTT: baseline vs. week 24. Black line with squares, baseline values at 0,
+30, +60, +120 and +180-min time points; grey line with squares, week 24 values at 0, +30, +60, +120 and +180-min
time points. aSample size at 120-min time point; badjusted mean change in 120-min PPG
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glyburide was )3.9, )3.2 and )2.0 mmHg (SBP),
and )3.3, )1.8 and )2.4 mmHg (DBP) respectively.
There were no clinically meaningful drug effects on
any other laboratory safety parameter.
There was no statistically significant difference in
the incidence of reported and confirmed hypoglycae-
mic events in the saxagliptin 2.5- and 5-mg treat-
ment groups vs. the uptitrated glyburide treatment
group (Table 3). Confirmed hypoglycaemia occurred
in 6 ⁄ 248 (2.4%), 2 ⁄ 253 (0.8%) and 2 ⁄ 267 (0.7%) of
patients in the saxagliptin 2.5- and 5-mg treatment
groups vs. the uptitrated glyburide treatment group.
Of the 10 confirmed hypoglycaemic events, most
were of mild or moderate intensity; a single hypo-
glycaemia-related AE judged to be severe in intensity
by the study investigator occurred in a patient
receiving saxagliptin 2.5 mg, which was easily man-
aged by the patient. No hypoglycaemic event was
judged by the study investigator to be an SAE or led
to discontinuation of study therapy.
Table 2 Other efficacy assessments at 24 weeks
n
Baseline
mean ± SE
Week 24
mean ± SE
Adjusted mean
change from
baseline ± SE 95% CI
PP insulin AUC (lUÆmin/ml)
SAXA 2.5 + GLY 184 6220 ± 293.7 7381 ± 340.8 1174 ± 211.8 (758, 1590)
SAXA 5 + GLY 192 5889 ± 227.0 7042 ± 292.6 1071 ± 207.5 (663, 1478)
PBO + UPGLY 200 6400 ± 373.6 5710 ± 269.6 )624 ± 203.2 ()1023, )224)
PP glucagon AUC (pgÆmin/ml)
SAXA 2.5 + GLY 183 13153 ± 388.2 12936 ± 377.4 )125 ± 275.5 ()667, 416)
SAXA 5 + GLY 188 12443 ± 321.3 12101 ± 312.3 )566 ± 272.2 ()1101, )32)
PBO + UPGLY 193 13244 ± 377.2 13884 ± 324.8 772 ± 268.3 (244, 1299)
PP C-peptide AUC (ngÆmin/ml)
SAXA 2.5 + GLY 163 1103 ± 32.7 1205 ± 32.8 107 ± 18.3 (71, 143)
SAXA 5 + GLY 161 1097 ± 33.9 1206 ± 35.1 113 ± 18.5 (77, 149)
PBO + UPGLY 175 1042 ± 30.8 1044 ± 27.1 )6 ± 17.7 ()41, 29)
HOMA-2b (%)
SAXA 2.5 + GLY 236 65.3 ± 2.18 74.4 ± 2.59 9.5 ± 2.32 (4.9, 14.0)
SAXA 5 + GLY 246 64.1 ± 2.23 71.8 ± 2.86 7.6 ± 2.27 (3.2, 12.1)
PBO + UPGLY 257 62.9 ± 2.29 67.9 ± 2.75 4.6 ± 2.22 (0.2, 8.9)
HOMA-2IR (no unit)
SAXA 2.5 + GLY 236 3.04 ± 0.095 3.14 ± 0.079 0.09 ± 0.067 ()0.04, 0.22)
SAXA 5 + GLY 246 3.14 ± 0.095 3.00 ± 0.086 )0.10 ± 0.065 ()0.23, 0.02)
PBO + UPGLY 257 3.01 ± 0.083 3.19 ± 0.086 0.15 ± 0.064 (0.03, 0.28)
OGIS (ml/minÆm2)
Unadjusted mean
change from
baseline ± SE
SAXA 2.5 + GLY 182 293.4 ± 3.93 284.5 ± 4.22 )8.9 ± 4.74 ()18.2, 0.5)
SAXA 5 + GLY 187 293.9 ± 4.28 290.0 ± 4.27 )3.9 ± 4.69 ()13.1, 5.4)
PBO + UPGLY 195 285.1 ± 4.14 285.9 ± 4.89 0.7 ± 4.67 ()8.5, 10.0)
Matsuda index (no unit)
SAXA 2.5 + GLY 176 3.67 ± 0.225 3.24 ± 0.207 )0.44 ± 0.181 ()0.79, )0.08)
SAXA 5 + GLY 179 3.44 ± 0.179 3.22 ± 0.154 )0.22 ± 0.142 ()0.51, 0.06)
PBO + UPGLY 188 3.51 ± 0.219 3.30 ± 0.169 )0.21 ± 0.156 ()0.52, 0.10)
Insulinogenic index (no unit)
SAXA 2.5 + GLY 180 0.29 ± 0.131 0.26 ± 0.030 )0.03 ± 0.132 ()0.29, 0.23)
SAXA 5 + GLY 186 0.22 ± 0.069 0.34 ± 0.103 0.12 ± 0.122 ()0.12, 0.36)
PBO + UPGLY 194 0.16 ± 0.013 0.16 ± 0.020 )0.00 ± 0.022 ()0.05, 0.04)
AUC, area under the curve; CI, confidence interval; HDL, high-density lipoprotein; HOMA, homeostatic model assessment; LDL, low-
density lipoprotein; OGIS, oral glucose insulin sensitivity; PP, postprandial; SE, standard error. SAXA 2.5 mg + GLY = saxagliptin
2.5 mg ⁄ day plus open-label glyburide 7.5 mg ⁄ day. SAXA 5 mg + GLY = saxagliptin 5 mg ⁄ day plus open-label glyburide 7.5 mg ⁄ day.
PBO + UPGLY = placebo plus double-blind glyburide 2.5 mg ⁄ day and open-label glyburide 7.5 mg ⁄ day.
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Discussion
The therapeutic goal for the treatment of type 2 diabe-
tes is to achieve and maintain glycaemic levels without
compromising safety or tolerability (22,23). This study
demonstrated that in patients with type 2 diabetes not
achieving glycaemic control on glyburide monothera-
py, the addition of saxagliptin once daily to submaxi-
mal doses of glyburide for 24 weeks provided
statistically significant and clinically meaningful reduc-
tions in key parameters of glycaemic control vs. upti-
trated glyburide, without statistically significantly
increasing the frequency of hypoglycaemia. Reductions
observed in HbA1c with saxagliptin added to submaxi-
mal glyburide corresponded to substantial improve-
ments in FPG, the proportion of patients reaching
goal, and PPG-AUC, with maximal benefits observed
in the saxagliptin 5-mg group. These 24-week results
are in contrast to increases in HbA1c, FPG and PPG-
AUC in the uptitrated glyburide group, indicating that
the addition of saxagliptin to submaximal glyburide
therapy is preferable to continued monotherapy with
higher doses of sulphonylurea.
HbA1c reductions achieved with saxagliptin added
to submaximal glyburide therapy occurred early.
Decreases relative to uptitrated glyburide were
noted by week 4 and were maintained throughout
the remainder of the treatment period. Importantly,
the effect of saxagliptin on HbA1c lowering was
consistent across prespecified subgroups including
age, gender, ethnicity, BMI, geographic distribution
and duration of diabetes, suggesting its appropriate-
ness for use in a variety of patients with type 2
diabetes.
More than twice as many patients treated with
saxagliptin 2.5 and 5 mg achieved HbA1c goals rec-
ommended by the ADA and European Association
for the Study of Diabetes (< 7.0%) vs. patients treat-
ed with uptitrated glyburide (24). Similarly, more
than twice as many patients treated with saxagliptin
Table 3 Safety and tolerability during 24-week treatment period by randomised group
SAXA 2.5 mg + GLY
(n = 248)
SAXA 5 mg + GLY
(n = 253)
PBO + UPGLY
(n = 267)
Adverse events (%)*
‡ 1 AE 186 (75.0) 183 (72.3) 205 (76.8)
‡ 1 related AE 49 (19.8) 54 (21.3) 38 (14.2)
Discontinuation due to AE 3 (1.2) 8 (3.2) 4 (1.5)
‡ 1 SAE 4 (1.6) 6 (2.4) 6 (2.2)
‡ 1 related SAE 0 0 0
Discontinuation due to SAEs 0 1 (0.4) 1 (0.4)
Deaths 0 0 1 (0.4)
Adverse events (‡ 5%),§
Urinary tract infection 13 (5.2) 27 (10.7) 22 (8.2)
Nasopharyngitis 14 (5.6) 15 (5.9) 18 (6.7)
Upper respiratory tract infection 11 (4.4) 16 (6.3) 18 (6.7)
Influenza 13 (5.2) 10 (4.0) 16 (6.0)
Diarrhoea 14 (5.6) 10 (4.0) 14 (5.2)
Back pain 12 (4.8) 15 (5.9) 12 (4.5)
Pain in extremity 11 (4.4) 9 (3.6) 15 (5.6)
Headache 19 (7.7) 19 (7.5) 15 (5.6)
Cough 13 (5.2) 10 (4.0) 13 (4.9)
Hypertension 9 (3.6) 16 (6.3) 6 (2.2)
Reported hypoglycaemia– 33 (13.3)** 37 (14.6) 27 (10.1)
Confirmed hypoglycaemia 6 (2.4)§§ 2 (0.8)–– 2 (0.7)
*AE defined as any new or worsening illness, sign, symptom, or clinically significant laboratory test abnormality as noted by the investiga-
tor during the course of the study, regardless of the investigator’s attribution of the event to study treatment. SAE defined as an AE that
was fatal, life threatening, required in-patient hospitalisation or prolonged an existing hospitalisation, resulted in persistent or significant
disability or incapacity, a cancer, a congenital anomaly ⁄ birth defect, resulted in the development of drug dependency or drug abuse, or
was an important medical event that jeopardised the patient or required intervention to prevent a serious outcome. Excludes hypogly-
caemia. §AEs outside of hypoglycaemia were not tested for statistical significance vs. comparator. –Reported hypoglycaemia was defined
as events consistent with signs or symptoms of hypoglycaemia with or without documented blood glucose levels. **p = 0.2741 vs.
PBO + UPGLY. p = 0.1417 vs. PBO + UPGLY. Confirmed hypoglycaemia was defined by a fingerstick glucose value £ 50 mg ⁄ dl
(2.8 mmol ⁄ l) with associated symptoms. §§p = 0.1626 vs. PBO + UPGLY. ––p = 1.0000 vs. PBO + UPGLY.
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5 mg achieved the American Association of Clinical
Endocrinologists’ recommended goal of HbA1c
£ 6.5%, compared with patients treated with uptitrat-
ed glyburide (25). Patients treated with saxagliptin
achieved HbA1c targets of < 7% more rapidly than
patients receiving uptitrated glyburide, potentially
reducing the harmful impact of glucotoxicity on beta-
cell function earlier in the disease course (26).
Relative to uptitrated glyburide, saxagliptin treat-
ment led to an increase in postprandial insulin. A pos-
sible explanation for this observation is that the
maximal insulin-releasing effect of a sulphonylurea
may be enhanced by the addition of another OAD
with a complementary mechanism of action also
known to increase insulin levels or beta-cell function.
DPP-4 inhibitors enhance GLP-1 and GIP levels,
thereby acting to promote insulin synthesis and release
and improve beta-cell function, suggesting their utility
in combination with sulphonylurea therapy.
Saxagliptin 2.5 and 5 mg were generally well
tolerated, with no clinically meaningful difference
between treatment groups in the proportion of
patients reporting AEs. There was no evidence of a
dose-response relationship for AEs. Combination
therapy is often associated with an increased risk for
hypoglycaemia, particularly combinations that use
sulphonylureas or insulin (27). Treatment with saxa-
gliptin did not statistically significantly increase the
frequency of hypoglycaemia, compared with glybu-
ride uptitration, even with significantly greater gly-
caemic efficacy achieved with add-on therapy.
Despite no observed statistically significant increase
in hypoglycaemia in this study, these results must be
viewed with appropriate caution given that hypo-
glycaemia is a concern in any sulphonylurea-based
therapeutic regimen.
An increase from baseline in body weight, of small
magnitude and unclear clinical relevance, occurred in
all treatment groups; however, weight gain was
higher in the saxagliptin treatment groups. Improved
glycaemic control has been shown to promote weight
gain in certain instances by decreasing glucosuria
(13,28). A possible explanation is that the weight
gain in the saxagliptin treatment groups was a result
of decreased glucosuria, whereas sulphonylurea-
induced weight gain may have been mitigated by the
glucosuria caused by inadequate glycaemic control in
the uptitration arm.
Only data collected prior to rescue were used for
efficacy and safety analyses, which could be a study
limitation in that experience following rescue therapy
is not included in the analyses. However, this
approach was taken to minimise the potential con-
founding of rescue therapy on both safety and effi-
cacy parameters.
In patients with type 2 diabetes and inadequate
glycaemic control, initiating therapy with a sulpho-
nylurea and uptitrating the dosage until maximum
concentrations are reached is an approach commonly
used in clinical practice in certain regions. The addi-
tion of saxagliptin to submaximal sulphonylurea
treatment – as opposed to uptitration – offers a
potentially improved strategy for achieving tighter
glycaemic control and contrasts with existing ‘treat-
to-failure’ approaches, in which clinical inertia often
leads to an unacceptable glycaemic burden (29).
Other randomised controlled studies of oral anti-
diabetic agents in combination with submaximal
sulphonylurea therapy have also demonstrated
improved glycaemic control, compared with uptitra-
tion of sulphonylurea monotherapy (30,31). Further,
the addition of saxagliptin to submaximal sulpho-
nylurea therapy has the potential to yield additional
benefits, such as preservation of beta-cell function
and reduction of potentially toxic beta-cell effects
associated with maximal sulphonylurea therapy
(15,16).
Conclusions
The glycaemic benefits demonstrated in this study
support the use of the DPP-4 inhibitor saxagliptin as
add-on therapy to glyburide or other sulphonylurea
agents in patients with type 2 diabetes and inadequate
glycaemic control with sulphonylurea monotherapy.
The favourable tolerability profile of combination
therapy assessed in the current trial indicates that the
addition of saxagliptin may be appropriate when a
submaximal dose of glyburide or other sulphonylurea
provides inadequate glycaemic control.
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